FFA
VYNE icon

Farther Finance Advisors’s VYNE Therapeutics VYNE Stock Holding History

Farther Finance Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16
Closed -$9 – 5903
2025
Q4 		$9 Hold
16
– – ﹤0.01% 5415
2025
Q3 		$5 Hold
16
– – ﹤0.01% 4936
2025
Q2 		$26 Buy
+16
New +$21 ﹤0.01% 4417

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Farther Finance Advisors's VYNE Position: Q1 2026 in Review

Farther Finance Advisors sold out of VYNE Therapeutics (VYNE) in Q1 2026, closing a stake of 16 shares — an estimated $9 sold.

Farther Finance Advisors first reported a position in VYNE in Q2 2025 and held it in 3 quarters. The position peaked at $26 in Q2 2025. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Farther Finance Advisors reported no remaining VYNE Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Farther Finance Advisors sold 16 VYNE Therapeutics shares in Q1 2026, an estimated $9.
  • Farther Finance Advisors first reported a position in VYNE Therapeutics in Q2 2025 and held it in 3 quarters.
  • Farther Finance Advisors's VYNE Therapeutics position peaked at $26 in Q2 2025.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.